Lupus Erythematosus accounted for a 12.2% share of the global clinical trials within the Immunology therapy area in 2021, registering an increase of 5.3% when compared with the last ten-year average of 6.9% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Lupus Erythematosus
Industry sponsored trials held a 62.5% share of all the clinical trials for Lupus Erythematosus indication in 2021, registering an increase of 7.2% when compared with the ten-year average of 55.3%. Non-industry sponsored trials accounted for a 37.5% share in 2021, marking a decrease of 7.2% over the ten-year average of 44.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Lupus Erythematosus trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Lupus Erythematosus trials, accounting for a 52.6% share in 2021, when compared with the five-year average of 39.0% and ten-year average of 43.6%.
Europe was at the second position with a 44.7% share in 2021, over the five-year average of 44.0% and ten-year average of 46.0%, followed by North America with a 42.1% share in 2021, as against five-year and ten-year averages of 62.3% and 62.5% respectively.
South and Central America stood fourth with a 17.1% share in 2021, compared with the five-year average of 18.8% and ten-year average of 21.8%, followed by Middle East and Africa with a 3.9% share in 2021, over five-year and ten-year averages of 10.5% and 13.3% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Lupus Erythematosus trials, accounting for a 42.1% share in 2021, as against the five-year average of 60.7% and ten-year average of 60.8%.
China held a 27.6% share in 2021, over the five-year average of 16.3% and ten-year average of 14.2%, followed by Russia with a 19.7% share in 2021, compared with the five-year and ten-year averages of 14.7% and 18.6% respectively.
Poland held a 17.1% share in 2021, as against the five-year average of 19.2% and ten-year average of 20.2%.
Spain held a 17.1% share in 2021, over the five-year and ten-year averages of 18.2% and 20.1% respectively.
Top regions of non-industry sponsored Lupus Erythematosus trials
Asia-Pacific was the top region for non-industry sponsored Lupus Erythematosus trials, accounting for a 44.9% share in 2021 when compared with the five-year average of 59.2% and ten-year average of 52.5%.
Europe was at the second position with a 28.6% share in 2021, over the five-year and ten-year averages of 13.0% and 16.4% respectively, followed by North America with a 14.3% share in 2021, as against the five-year average of 17.5% and ten-year average of 21.6%.
Middle East and Africa stood at the fourth position with an 8.2% share in 2021, compared with the five-year average of 6.8% and ten-year average of 7.5%, followed by South and Central America with a 4.1% share in 2021, over the five-year and ten-year averages of 5.9% and 5.4% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Lupus Erythematosus trials, accounting for a 34.7% share in 2021, as against the five-year average of 34.0% and ten-year average of 25.6%.
The US held a 12.2% share in 2021, over the five-year average of 16.3% and ten-year average of 20.6%, followed by Egypt with a 6.1% share, compared with the five-year and ten-year averages of 2.4% and 1.2% respectively.
France held a 6.1% share in 2021, as against the five-year average of 4.5% and ten-year average of 6.6%.
Germany held a 6.1% share in 2021, over the five-year average of 2.0% and ten-year average of 2.6%.
Phase I trials lead industry sponsored clinical trials for Lupus Erythematosus in 2021
Phase I trials held a 57.6% share of industry sponsored clinical trials for Lupus Erythematosus in 2021, over the five-year average of 58.8% and ten-year average of 51.3%.
Phase II trials held an 18.8% share in 2021, as against the five-year average of 27.1% and ten-year average of 29.8%. Phase III trials held a 12.9% share in 2021, compared with the five-year and ten-year averages of 9.6% and 11.8% respectively.
Phase IV trials held a 10.6% share in 2021, over the five-year average of 4.5% and ten-year average of 7.1%.
Phase IV trials lead non-industry sponsored clinical trials for Lupus Erythematosus in 2021
Phase IV trials held a 37.3% share of non-industry sponsored clinical trials for Lupus Erythematosus in 2021, over the five-year average of 24.5% and ten-year average of 24.9%.
Phase II trials held a 31.4% share in 2021, as against the five-year average of 53.8% and ten-year average of 52.7%. Phase I trials held a 19.6% share, compared with the five-year and ten-year averages of 14.8% and 11.9% respectively.
Phase III trials held a 11.8% share in 2021, over the five-year average of 7.0% and ten-year average of 10.5%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
